Clinical Trial Search

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 3 Days of N6LS Product Administration Alone or N6LS Co-Administered With rHuPH20 — 3; 1…

Primary: Difference in the Two Hour and Four Hour Post Prandial Blood Glucose Levels Following Administration of Insulin Glulisine Versus Insulin Aspart at the End of the Twenty…

Primary: Post-prandial Glucose Excursion — 6.8; 5.6; 25.9; 21.9 mg/dL

Primary: Change From Baseline of Wakefulness After Sleep Onset (WASO) Measured by Polysomnography (PSG) — 100.88; 99.70; 103.51; 48.64 Minutes

Primary: Number of Participants With Solicited Local Adverse Events (AEs) (e.g., Injection Site Pain, Redness, Induration, Swelling) Recorded up to 14 Days After Each Dose of…

Primary: The Percentage of Patients Who Receive the First XR-NTX Injection (Dichotomous: Did or Did Not Receive First Dose of XR-NTX) — 68; 141 Participants

Primary: Change From Baseline to Week 12 in the CMAI Total Score — -22.6; -17.3 score on a scale — p=0.0026

Primary: Virological Suppression at 24 Weeks — 43; 44 Participants

Primary: Percentage of Patients Considering the Treatment a Success After 5 Years — 81.7; 87.3; 31.2; 91.7 percentage of success

Primary: Body Fat Assessment by Investigator — 1.88 score on a scale

Primary: Change in Preconception Health Knowledge — 58.1; 14.8; 4.3 percentage change pre to post test

Primary: Artificial Hand Grasp Performance Metrics — 90.6 percentage of successful transportation

Primary: Dyad Congruence on Goals-of-Care Tool — 98; 76; 133; 119 dyads

Primary: Psychomotor Speed — 54.2; 60.4; 53.4 score on a scale — p=0.40

Primary: Event-Free Survival (EFS) — 11.24; 7.72 months — p==0.477